• Search

Search in Site

PharmaDeviceNews | Pharma and Medical Device Industry News PharmaDeviceNews.com
  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»Kalohexis Inc.

Kalohexis 710GO data highlight a differentiated obesity mechanism as Phase 1 moves ahead

By Pallavi Madhiraju on June 16, 2026   Pharma & Biotech  

Kalohexis 710GO data highlight a differentiated obesity mechanism as Phase 1 moves ahead

Read how Kalohexis’ 710GO could challenge GLP-1 obesity drugs with dual MC3R/MC4R activation, lean-mass sparing and durability.

Recent Posts

  • AI meets nuclear medicine as Sanyou Bio and Baiyunshan Xihe pursue cancer diagnostics
  • Why Brii Bio’s BRII-179 sequencing data could reshape hepatitis B combination treatment
  • Lucerno Dynamics asset deal gives Radnostix new route into nuclear medicine workflows
  • Butterfly Network enters Brazil with iQ+ and iQ3 handheld ultrasound systems
  • Endologix DETOUR2 three-year data strengthen case for percutaneous bypass in complex SFA disease
  • Why Permeasis MTD4 could reshape enzyme replacement and intracellular drug discovery
  • Oliva Therapeutics targets thyroid treatment demand with U.S.-made Amerithroid tablets
  • ITI-9001 enters Phase 1 as Immunomic Therapeutics tests disease-modifying allergy vaccine
  • Visby Medical’s FDA-cleared at-home PCR could reshape flu and COVID-19 testing
  • Is Vilo Signal OS truly different from Oura Advisor and WHOOP’s proactive AI?
  • Evidation GLP-1 study reveals major growth runway but exposes widening access gaps
  • Why the Nona Biosciences and Lonza alliance matters for brain-penetrant biologics
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes